Dubai’s connectivity remains strong in an uncertain world 
FDA Weighs Safety Standards for Psychedelic Therapies 
Novartis Shares Plunge After Muscle Drug Fails Phase III Trial 
Novo Nordisk Strikes €1.17 Billion Nanexa Drug Delivery Deal 
Airbus Finds A321neo Fuselage Quality Issue 
OpenAI to Preview GPT-6 Cyber AI Model for Cybersecurity 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
US 10-Year Treasury Yield at 6% Emerges as New Market Risk Threshold 
Meta Unveils Muse Charm AI Device, Expands Smart Glasses Lineup 
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children 
U.S. Issues Cuba Health Alert as Illnesses Rise 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback 
SpaceXAI to Double Nvidia Chips at Colossus 2 by Year-End 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
Add as a preferred source on Google
Merck is reportedly close to finalizing a deal to acquire Cidara Therapeutics, offering a premium over the biotechnology company’s current market value of about $3.3 billion. According to a report from the Financial Times, the agreement could be announced as early as Friday, assuming no last-minute complications arise. Sources familiar with the negotiations said Merck had been competing with another major pharmaceutical company up until late Thursday, but Cidara ultimately moved forward with Merck’s proposal.
Although the exact purchase price has not been disclosed, the deal is expected to consist of an upfront cash payment along with additional milestone-based payouts tied to future clinical achievements. Such structures are commonly used in the biotech sector, particularly when promising drug candidates are still in development.
Cidara Therapeutics declined to comment on the report, and Merck has not yet issued an official response. The potential acquisition comes at a pivotal moment for Cidara, which recently received breakthrough therapy designation from the U.S. Food and Drug Administration for its investigational drug CD388. The treatment is designed to prevent influenza A and B in individuals at high risk of severe illness, a population with significant unmet medical needs. The FDA’s breakthrough designation is intended to accelerate the development and review of innovative therapies that could offer substantial clinical benefits.
Industry analysts note that Merck’s interest in Cidara underscores its strategy to strengthen its infectious disease pipeline and expand its portfolio of next-generation antiviral treatments. If finalized, the acquisition would position Merck to capitalize on growing market demand for advanced flu prevention options, especially following heightened global awareness of respiratory viruses in recent years.
The reported deal highlights the increasing competition among pharmaceutical companies to secure cutting-edge biotech assets with strong clinical potential, reinforcing the value of innovative drug platforms in today’s healthcare landscape.
